652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III
0 activities
A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
1 activities
A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
1 activities
Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency
1 activities
Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency
Development of a Novel and Rapid Diagnostic Technique for Cardiac Amyloidosis Using Raman Spectroscopy
1 activities
Development of a Novel and Rapid Diagnostic Technique for Cardiac Amyloidosis Using Raman Spectroscopy
Differences in Immune Cell Populations between Individuals with or without MGUS
1 activities
Differences in Immune Cell Populations between Individuals with or without MGUS
Different Patterns of Antigen Expression in Bone Marrow and Circulating Tumor Plasma Cells in Patients with MGUS and Smoldering Multiple Myeloma
1 activities
Different Patterns of Antigen Expression in Bone Marrow and Circulating Tumor Plasma Cells in Patients with MGUS and Smoldering Multiple Myeloma
Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US
1 activities
Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US
Evaluation of Functional Cardiac Measures and Response to Treatment Initiation in Patients with Systemic Light-Chain (AL) Amyloidosis: Results from a Single Site Retrospective Study
1 activities
Evaluation of Functional Cardiac Measures and Response to Treatment Initiation in Patients with Systemic Light-Chain (AL) Amyloidosis: Results from a Single Site Retrospective Study
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
1 activities
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis
1 activities
Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis
Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
1 activities
Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd
1 activities
Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd
Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis
1 activities
Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis
Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd
1 activities
Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd
Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
1 activities
Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)